Latest News and Events
Filter by
Selections
January 6, 2020
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Read MoreDecember 20, 2019
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Read MoreDecember 16, 2019
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Read MoreDecember 16, 2019
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
Read MoreDecember 13, 2019
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
Read MoreDecember 11, 2019
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreDecember 6, 2019
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
Read MoreDecember 4, 2019